Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
TV & Film
Technology
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/1c/11/8b/1c118bc2-3dc0-6de1-7ec7-9e94a9249005/mza_8173629372850482093.jpg/600x600bb.jpg
Healthcare Weekly: At the Forefront of Healthcare Innovation
Codrin Arsene, Michael Reddy
55 episodes
9 months ago
How is technology reshaping the healthcare industry? The Healthcare Weekly podcast reframes the conversation about the delivery of care in the US and beyond. Join hosts Codrin Arsene and Michael Reddy as they interview the best & brightest in healthcare to explore how new innovations — including artificial intelligence, blockchain, virtual reality and big data — are improving patient outcomes and changing the healthcare experience.
Show more...
Technology
Health & Fitness,
Science
RSS
All content for Healthcare Weekly: At the Forefront of Healthcare Innovation is the property of Codrin Arsene, Michael Reddy and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
How is technology reshaping the healthcare industry? The Healthcare Weekly podcast reframes the conversation about the delivery of care in the US and beyond. Join hosts Codrin Arsene and Michael Reddy as they interview the best & brightest in healthcare to explore how new innovations — including artificial intelligence, blockchain, virtual reality and big data — are improving patient outcomes and changing the healthcare experience.
Show more...
Technology
Health & Fitness,
Science
https://image.simplecastcdn.com/images/402aea7c-0686-4e53-b0c7-560a1e14df8f/ef4a161b-67e1-4d12-9d7f-553b1f8a82b3/3000x3000/photo-dr-anand-giostar-chairman-and-co-founder.jpg?aid=rss_feed
Are Stem Cells the Answer to COVID-19 long term damage to the human body?
Healthcare Weekly: At the Forefront of Healthcare Innovation
38 minutes 22 seconds
5 years ago
Are Stem Cells the Answer to COVID-19 long term damage to the human body?
Today’s guest is Dr. Anand Srivastava. He is the Co-founder, Chairman and Chief Scientific Officer of GIOSTAR. GIOSTAR is the Global Institute of Stem Cell Therapy and Research. Under Dr. Anand’s leadership, scientists and clinicians have developed and established stem cell therapies for various types of autoimmune diseases and blood disorders. Dr. Anand joins us today to discuss his experience in the field of stem cell research, the uses for stem cells and how they could be employed to battle COVID-19. Listen to the podcast to learn about: Public vs. government perspectives on stem cell research The history of stem cell research The modern approach to stem cell therapy: regenerative medicine Understanding the spectrum of diseases humans are prone to How stem cells can be applied to help with metabolic malfunction Regenerative medicine to battle degenerative disease How the connotations of ‘embryonic’ impacted perceptions The multi-national effort to research stem cell applications to battle COVID-19 The importance of understanding the physiology of the COVID-19 virus Why people with underlying conditions and the elderly are more affected by COVID-19 How the coronavirus could impact perceptions of stem cell research The continuing necessity of a vaccine Why we need a multiple approach strategy to tackle COVID-19 Potential issues meeting supply and demand of stem cells in the future What the future of the industry holds
Healthcare Weekly: At the Forefront of Healthcare Innovation
How is technology reshaping the healthcare industry? The Healthcare Weekly podcast reframes the conversation about the delivery of care in the US and beyond. Join hosts Codrin Arsene and Michael Reddy as they interview the best & brightest in healthcare to explore how new innovations — including artificial intelligence, blockchain, virtual reality and big data — are improving patient outcomes and changing the healthcare experience.